Disruption of sarcolemmal dystrophin and Β-dystroglycan may be a potential mechanism for myocardial dysfunction in severe sepsis

Laboratory Investigation

Volumn 90, Issue 4, 2010, Pages 531-542

  Celes, Mara Rbia N ^a   Torres Duẽas, Diego ^a,b   Malvestio, Lygia M ^a   Blefari, Valdecir ^a   Campos, Erica C ^a   Ramos, Simone G ^a   Prado, Cibele M ^a   Cunha, Fernando Q ^a   Rossi, Marcos A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

Author keywords

dystroglycan; Dystrophin; Dystrophin glycoprotein complex (DGC); Myocardial dysfunction; Sarcolemmal permeability; Sepsis; Septic cardiomyopathy

Indexed keywords

ALBUMIN; ANTIOXIDANT; BETA DYSTROGLYCAN; DYSTROPHIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LAMININ ALPHA2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL PERITONITIS; CARDIOMYOPATHY; CAROTID ARTERY; CECUM; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; INFLAMMATION; INTESTINE INJURY; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUNCTURE; SARCOLEMMA; SEPSIS; SHAM PROCEDURE; SURVIVAL RATE;

ANIMALS; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DYSTROGLYCANS; DYSTROPHIN; MALE; MICE; MYOCYTES, CARDIAC; SARCOLEMMA; SEPSIS;

EID: 77950350671     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.3     Document Type: Article

References (39)

1. Allikian MJ, Mcnally EM. Processing and assembly of the dystrophin glycoprotein complex. Traffic 2007;8:177-183.
2. Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 2006;7:762-773.
3. Jennings RB, Reimer KA, Steenbergen C. Myocardial ischemia revisited. The osmolar load, membrane damage, and reperfusion. J Mol Cell Cardiol 1986;18:769-780.
4. Parker MM, Shelhamer JH, Bacharach SL, et al. JE: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984;100:483-490.
5. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans. Advances in understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113:227-242.
6. Rossi MA, Celes MR, Prado CM, et al. Myocardial structural changes in long-term human severe sepsis/septic shock may be responsible for cardiac dysfunction. Shock 2007;27:10-18.
7. Celes MR, Torres-Dueñas D, Prado CM, et al. Shock 2010, (in press).
8. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock: a review of laboratory models and a proposal. J Surg Res 1980;29:189-201.
9. Hubbard WJ, Choudhry M, Schwacha MG, et al. Cecal ligation and puncture. Shock 2005;24:52-57.
10. Yu XW, Chen Q, Kennedy RH, et al. Inhibition of sarcoplasmic reticular function by chronic interleukin-6 exposure via iNOS in adult ventricular myocytes. J Physiol 2005;566:327-340.
11. Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care 2009;15:392-397.
12. Standiford TJ, Kunkel SL, Lukacs NW, et al. Macrophage inflammatory protein-1 alpha mediates lung leukocyte recruitment, lung capillary leak, and early mortality in murine endotoxemia. J Immunol 1995;155:1515-1524.
13. Speyer CL, Gao H, Rancilio NJ, et al. Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am J Pathol 2004;165:2187-2196.
14. 2+ signaling and reactive oxygen species-generating pathways. Cardiovasc Res 2008;77:766-773.
15. Danialou G, Comtois AS, Dudley R, et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J 2001;15:1655-1657.
16. Khairallah M, Khairallah R, Young ME, et al. Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy. J Mol Cell Cardiol 2007;43:119-129.
17. Wu B, Moulton HM, Iversen PL, et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 2008;105: 14814-14819.
18. Williamson RA, Henry MD, Daniels KJ, et al. Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet 1997;6:831-841.
19. Pittet D, Rangel-Frausto S, Li N, et al. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 1995;21:302-309.
20. Sgambato A, Brancaccio A. The dystroglycan complex: from biology to cancer. J Cell Physiol 2005;205:163-169.
21. Matsumura K, Arai K, Zhong D, et al. Disruption of dystroglycan axis by beta-dystroglycan processing in cardiomyopathic hamster muscle. Neuromuscul Disord 2003;13:796-803.
22. Salvemini D, Cuzzocrea S. Oxidative tress in septic shock and disseminated intravascular coagulation. Free Radic Biol Med 2002;33:1173-1185.
23. Cuzzocrea S, Riley DP, Caputi AP, et al. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/ reperfusion injury. Pharmacol Rev 2001;53:135-159.
24. Rodŕiguez M, Cai W-J, Kostin S, et al. Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanisms of myocardial ischemic injury. J Mol Cell Cardiol 2005;38: 723-733.
25. den Uil CA, Klijn E, Lagrand WK, et al. The microcirculation in health and critical disease. Prog Cardiovasc Dis 2008;51:161-170.
26. Straub V, Bittner RE, Léger JJ, et al. Direct visualization of the dystrophin network on skeletal muscle fiber membrane. J Cell Biol 1992;119:1183-1191.
27. Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol 2000;150:1209-1214.
28. Ervasti JM, Ohlendieck K, Kahl SD, et al. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 1990;345:315-319.
29. Reggiani C. Between channels and tears: aim at ROS to save the membrane of dystrophic fibres. J Physiol 2008;586:1779.
30. Messina S, Bitto A, Aguennouz M, et al. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in mdx mice. Exp Neurol 2006;198:234-241.
31. Hinshaw LB. Sepsis/septic shock. Participation of the microcirculation: an abbreviated review. Crit Care Med 1996;24:1072-1078.
32. Rossi MA, Santos CS. Sepsis related microvascular myocardial damage with the giant cell inflammation and calcification. Virchows Arch 2003;443:87-92.
33. Chagnon F, Bentourkia M, Lecomte R, et al. Endotoxin-induced heart dysfunction in rats: assessment of myocardial perfusion and permeability and the role of fluid resuscitation. Crit Care Med 2006;34:127-133.
34. Campos EC, Romano MM, Prado CM, et al. Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury. Int J Exp Pathol 2008;89:367-381.
35. Armstrong Sc, Latham CA, Shivell CL, et al. Ischemic loss of sarcolemmal dystrophin and spectrin: correlation with myocardial injury. J Mol Cell Cardiol 2001;33:1165-1179.
36. Armstrong SC, Latham CA, Ganote CE. An ischemic beta-dystroglycan (betaDG) degradation product: correlation with irreversible injury in adult rabbit cardiomyocytes. Mol Cell Biochem 2003;242:71-79.
37. Badorff C, Lee GH, Lamphear BJ, et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999;5:320-326.
38. Xiong D, Yajima T, Lim BK, et al. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 2007;115:94-102.
39. Whitehead NP, Yeung EW, Allen DG. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 2006;33:657-662.